UK Markets close in 8 hrs 26 mins

Akebia Therapeutics, Inc. (AKBA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.7100+0.0400 (+1.50%)
At close: 04:00PM EST
2.7300 +0.02 (+0.74%)
After hours: 05:39PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.67
52-week change 3N/A
S&P500 52-week change 3N/A
52-week high 35.1400
52-week low 32.3500
50-day moving average 32.8418
200-day moving average 33.0923

Share statistics

Avg vol (3-month) 32.09M
Avg vol (10-day) 32.91M
Shares outstanding 5160.12M
Implied shares outstanding 6N/A
Float 8172.81M
% held by insiders 11.04%
% held by institutions 158.63%
Shares short (29 Sept 2021) 412.69M
Short ratio (29 Sept 2021) 46.42
Short % of float (29 Sept 2021) 48.43%
Short % of shares outstanding (29 Sept 2021) 47.27%
Shares short (prior month 30 Aug 2021) 413.38M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021

Profitability

Profit margin -135.00%
Operating margin (ttm)-98.73%

Management effectiveness

Return on assets (ttm)-20.18%
Return on equity (ttm)-109.96%

Income statement

Revenue (ttm)221.9M
Revenue per share (ttm)1.47
Quarterly revenue growth (yoy)-41.30%
Gross profit (ttm)12.86M
EBITDA -185.72M
Net income avi to common (ttm)-299.58M
Diluted EPS (ttm)-2.7090
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)246.99M
Total cash per share (mrq)1.41
Total debt (mrq)124.23M
Total debt/equity (mrq)71.14
Current ratio (mrq)2.00
Book value per share (mrq)1.35

Cash flow statement

Operating cash flow (ttm)-191.91M
Levered free cash flow (ttm)-48.58M